• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

西班牙的高效卫生技术是什么?

[What is an efficient health technology in Spain?].

作者信息

Sacristán J A, Oliva J, Del Llano J, Prieto L, Pinto J L

机构信息

Departamento de Investigación Clínica, Lilly S.A. Madrid, Spain.

出版信息

Gac Sanit. 2002 Jul-Aug;16(4):334-43. doi: 10.1016/s0213-9111(02)71933-x.

DOI:10.1016/s0213-9111(02)71933-x
PMID:12113733
Abstract

INTRODUCTION

Despite the growing recognition of the potential applications of cost-effectiveness assessments, a criterion to establish what is an efficient health technology does not exist in Spain. The objective of this work is to describe the limits and the criteria used in Spain to recommend the adoption of health interventions.

METHOD

A review of the economic evaluations of health technologies published in Spain from 1990 to 2001 was conducted. Complete economic assessments in which the cost-effectiveness ratio was expressed as cost per life-year gained (LYG), cost per quality-adjusted-life-year (QALY) or cost per saved live were selected. Those interventions in which the authors established recommendations (adoption or rejection) and the criteria used were analyzed.

RESULTS

Twenty (20%) of the 100 complete economic evaluations fulfilled the selection criteria. In16 studies, the results were expressed as cost per LYG, in 6 studies as cost per QALY and in 1 as cost per saved live. A total of 82 health interventions were assessed and some kind of recommendation was established in 44 of them. All technologies with a cost-effectiveness ratio lower than 30,000 euros (5 million pesetas) per LYG were recommended for adoption by the authors. Up to that limit there was no a clear tendency.

CONCLUSIONS

Although the results must be interpreted with much precaution, given the limitations of the study, the limits of cost-effectiveness presented in this work could be a first reference to which would be an efficient health intervention in Spain.

摘要

引言

尽管成本效益评估的潜在应用得到了越来越多的认可,但西班牙尚无确定何种健康技术为高效技术的标准。本研究的目的是描述西班牙在推荐采用健康干预措施时所使用的限制条件和标准。

方法

对1990年至2001年在西班牙发表的健康技术经济评估进行综述。选取了完整的经济评估,其中成本效益比以每获得的生命年(LYG)成本、每质量调整生命年(QALY)成本或每挽救生命成本来表示。分析了作者在其中提出建议(采用或拒绝)的那些干预措施及其所使用的标准。

结果

100项完整的经济评估中有20项(20%)符合选择标准。16项研究的结果以每LYG成本表示,6项研究以每QALY成本表示,1项研究以每挽救生命成本表示。总共评估了82项健康干预措施,其中44项提出了某种建议。作者建议采用所有成本效益比低于每LYG 30,000欧元(500万比塞塔)的技术。在该限制范围内没有明显趋势。

结论

尽管鉴于本研究的局限性,结果必须谨慎解读,但本研究中提出的成本效益限制可能是西班牙高效健康干预措施的首个参考依据。

相似文献

1
[What is an efficient health technology in Spain?].西班牙的高效卫生技术是什么?
Gac Sanit. 2002 Jul-Aug;16(4):334-43. doi: 10.1016/s0213-9111(02)71933-x.
2
The use of cost per life year gained as a measurement of cost-effectiveness in Spain: a systematic review of recent publications.使用获得的每生命年成本作为西班牙成本效益的衡量标准:对近期出版物的系统回顾。
Eur J Health Econ. 2012 Dec;13(6):723-40. doi: 10.1007/s10198-011-0326-y. Epub 2011 Jun 10.
3
The use of quality-adjusted life-years in the economic evaluation of health technologies in Spain: a review of the 1990-2009 literature.在西班牙,使用质量调整生命年来对卫生技术进行经济评估:对 1990-2009 年文献的综述。
Value Health. 2011 Jun;14(4):458-64. doi: 10.1016/j.jval.2010.10.039.
4
Estimating the Reference Incremental Cost-Effectiveness Ratio for the Australian Health System.估算澳大利亚卫生系统的参考增量成本-效果比。
Pharmacoeconomics. 2018 Feb;36(2):239-252. doi: 10.1007/s40273-017-0585-2.
5
[The cost-effectiveness of pneumococcal vaccination in Catalonia].
Rev Esp Salud Publica. 1995 Sep-Oct;69(5):409-17.
6
7
[What is an efficient health intervention in Spain in 2020?].[2020年西班牙有效的健康干预措施是什么?]
Gac Sanit. 2020 Mar-Apr;34(2):189-193. doi: 10.1016/j.gaceta.2019.06.007. Epub 2019 Sep 24.
8
Cost effectiveness of prostacyclins in pulmonary arterial hypertension.前列腺素类药物治疗肺动脉高压的成本效益。
Appl Health Econ Health Policy. 2012 May 1;10(3):175-88. doi: 10.2165/11630780-000000000-00000.
9
Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.韩国心血管健康干预个体化微观模拟模型评估韩国人群进行心血管疾病一级预防应用他汀类药物治疗的成本效果分析结果
Clin Ther. 2009 Dec;31(12):2919-30; discussion 2916-8. doi: 10.1016/j.clinthera.2009.12.013.
10
Self-monitoring of blood glucose (SMBG) in patients with type 2 diabetes on oral anti-diabetes drugs: cost-effectiveness in France, Germany, Italy, and Spain.口服降糖药治疗的 2 型糖尿病患者的自我血糖监测(SMBG):法国、德国、意大利和西班牙的成本效益。
Curr Med Res Opin. 2010 Jan;26(1):163-75. doi: 10.1185/03007990903429765.

引用本文的文献

1
Cost-Effectiveness of Once-Daily Single-Inhaler COPD Triple Therapy in Spain: IMPACT Trial.在西班牙,每日一次的 COPD 三联单吸入器治疗的成本效益:IMPACT 试验。
Int J Chron Obstruct Pulmon Dis. 2022 Dec 16;17:3097-3109. doi: 10.2147/COPD.S366765. eCollection 2022.
2
Economic impact of the first pass effect in mechanical thrombectomy for acute ischaemic stroke treatment in Spain: a cost-effectiveness analysis from the national health system perspective.西班牙急性缺血性脑卒中机械取栓治疗中首次通过效应的经济影响:基于国家卫生体系视角的成本效益分析。
BMJ Open. 2022 Sep 1;12(9):e054816. doi: 10.1136/bmjopen-2021-054816.
3
Supply-Side Cost-Effectiveness Thresholds: Questions for Evidence-Based Policy.
供给侧成本效益阈值:循证政策的问题。
Appl Health Econ Health Policy. 2022 Sep;20(5):651-667. doi: 10.1007/s40258-022-00730-3. Epub 2022 Jun 7.
4
The Cost-Effectiveness of Oral Semaglutide in Spain: A Long-Term Health Economic Analysis Based on the PIONEER Clinical Trials.口服司美格鲁肽在西班牙的成本效益:基于 PIONEER 临床试验的长期健康经济分析。
Adv Ther. 2022 Jul;39(7):3180-3198. doi: 10.1007/s12325-022-02156-8. Epub 2022 May 12.
5
Cost-Effectiveness Analysis of Fracture Liaison Services Compared with Standard of Care in the Secondary Prevention of Fragility Fractures in Spain.西班牙脆性骨折二级预防中骨折联络服务与标准护理的成本效益分析
Clinicoecon Outcomes Res. 2022 Apr 22;14:249-264. doi: 10.2147/CEOR.S350790. eCollection 2022.
6
Clinical and economic impact of an alert system in primary care for the detection of patients with chronic hepatitis C.基层医疗中慢性丙型肝炎患者检测警报系统的临床和经济影响。
PLoS One. 2021 Dec 20;16(12):e0260608. doi: 10.1371/journal.pone.0260608. eCollection 2021.
7
Cost-effectiveness of a follow-up program for older patients with heart failure: a randomized controlled trial.老年心力衰竭患者随访计划的成本效益:一项随机对照试验。
Eur Geriatr Med. 2018 Aug;9(4):523-532. doi: 10.1007/s41999-018-0074-y. Epub 2018 Jun 6.
8
Real-World Cost-Effectiveness Analysis of Spinal Cord Stimulation vs Conventional Therapy in the Management of Failed Back Surgery Syndrome.脊髓刺激与传统疗法治疗腰椎手术失败综合征的真实世界成本效益分析
J Pain Res. 2021 Sep 24;14:3025-3032. doi: 10.2147/JPR.S326092. eCollection 2021.
9
Cost-Effectiveness Analysis of a Once-Daily Single-Inhaler Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease (COPD) Using the FULFIL Trial: A Spanish Perspective.使用 FULFIL 试验评估慢性阻塞性肺疾病(COPD)患者每日一次三联单吸入器治疗的成本-效果分析:西班牙视角。
Int J Chron Obstruct Pulmon Dis. 2020 Jul 10;15:1621-1632. doi: 10.2147/COPD.S240556. eCollection 2020.
10
Cost-effectiveness analysis of chronic hepatitis C treatment in the prison population in Spain.西班牙监狱人群慢性丙型肝炎治疗的成本效益分析。
Rev Esp Sanid Penit. 2020 May-Aug;22(2):66-74. doi: 10.18176/resp.00012. Epub 2020 Jul 20.